OnVagus Received Approval for Cancer Device Trial

The Houston-based clinical study will test a nerve-stimulation device for patients suffering from cachexia.

Updated on Oct. 7, 2026 in Cancer

Isometric editorial illustration showing a sterile medical probe on a steel tray, representing clinical research. — The FDA has approved the first clinical trial of a noninvasive nerve-stimulation device designed to treat cachexia in pancreatic cancer patients. AI Illustration. Upload story photo >

Live Poll

Should medical research prioritize noninvasive device-based treatments for cancer-related symptoms?

The FDA has authorized the first human trial for a noninvasive device designed to stimulate the vagus nerve in patients with pancreatic cancer. MD Anderson Cancer Center will host the study, which aims to address the effects of cachexia.

Why it matters

Cachexia causes severe muscle and weight loss that is unresponsive to nutritional intervention and currently lacks FDA-approved therapies. This condition frequently prevents patients from continuing necessary chemotherapy treatments.

The initial safety lead-in trial will enroll 10 patients over an eight-week period. If outcomes are positive, researchers plan a follow-up randomized, double-blind study involving 120 participants.

The players

MD Anderson Cancer Center

This Houston institution is a world-renowned facility dedicated to cancer patient care, research, and prevention.

OnVagus

This medical technology company is developing noninvasive nerve-stimulation devices for patient treatment.

National Cancer Institute

This federal agency is the primary government body responsible for cancer research and training.

The details

The device provides electrical stimulation through the skin to modulate the vagus nerve, potentially counteracting the muscle wasting associated with cancer. Funding for the research is provided by the National Cancer Institute, NIH, American Cancer Society, and BrightEdge.

A preclinical study on vagal blockade was published in 2025.
The first patient is expected to enroll in October 2026.
The safety lead-in trial will span eight weeks.

The Big Picture

This study follows a pattern set by the National Cancer Institute's cancer cachexia research initiative to find new treatments for metabolic wasting.

Patients experiencing cachexia may eventually gain access to a new, noninvasive treatment option that could improve their ability to remain on chemotherapy. The trial's initial focus on safety will determine if the device is a viable long-term solution for clinical use.

The takeaway

Advancements in neuro-stimulation offer a promising new avenue for managing the debilitating symptoms of terminal or severe illness. Patients should consult their oncologists regarding the eligibility requirements for emerging clinical trials.